ReviewCurrent microbiology2026
An update on Escalating Drug Resistance among Uropathogenic Bacteria: Challenges in Treatment and Scope for Maneuver.
Review in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uropathogens are among the most common infectious agents in humans worldwide. The problem is further exacerbated by the escalating emergence and dissemination of antibiotic resistance genes (ARGs) among bacteria causing urinary tract infections (UTIs). The World Health Organization (WHO) has identified antibiotic resistance as the most serious public health threat of this century, demanding global action. The most common bacteria contributing approximately 85% of UTIs include Escherichia coli, Klebsiella pneumoniae, and Enterococcus spp. Reports of intrinsic and/ or acquired resistance mechanisms contributing to the emergence and dissemination of multidrug-resistant (MDR) bacteria are on the rise. This review updates the escalating drug resistance among uropathogenic bacteria, scrutinizing the resistance genes, resistance mechanisms, and associated virulence factors such as fimbriae, α-hemolysin (HlyA), Esp, Ebp, Hyaluronidase, etc., which contribute to their persistence and proliferation in healthcare and communal settings. Furthermore, we have discussed the challenges in treatment due to resistance, scope for maneuver, and strategies to counter this menace, including the alternate approaches, viz., vaccines targeting virulence factors, small molecules targeting toxins, plasmid curing compounds, and antiplasmid systems.
Indexed as
Identifiers
41860740What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.